Download PDF
Arzneimittelforschung 2008; 58(2): 62-70
DOI: 10.1055/s-0031-1296470
Antihypertensives
Editio Cantor Verlag Aulendorf (Germany)

Absorption, Protein Binding, Pharmacokinetics and Excretion of the Anti-ischemic and Anti-hypertensive Arylpiperazine Derivative CDRI-93/478 in Rats

Jawahar Lal
Pharmacokinetics & Metabolism Division, Central Drug Research Institute, Lucknow, India
,
Ram Chandra Gupta
Pharmacokinetics & Metabolism Division, Central Drug Research Institute, Lucknow, India
› Author Affiliations
Further Information

Publication History

Publication Date:
15 December 2011 (online)

    Permissions and Reprints

Abstract

CDRI-93/478 (1-[4-(4-fluorophenyl)piper-azine-1-yl]-3-(2-oxopyrrolidin-1-yl)propane hydrochloride, an arylpiperazine derivative, is a potent anti-ischemic and anti-hypertensive agent and is in advanced stage of preclinical trials. In order to develop CDRI-93/478 into a clinical agent, the absorption, protein binding, pharmacokinetics, and excretion of the compound were investigated in male Sprague-Dawley rats. Oral absorption was evaluated in situ and in vivo, using the portal-venous concentration difference method. The compound showed negligible absorption (ka = 0.01 h-1) at pH 2.6. However, the rate of absorption of the compound at pH 7.4 was 0.6 h−1 and was comparable to that observed in the in vivo study (ka, >0.58 h−1) in rats after a single 2 mg/kg oral dose. In vitro and in vivo protein binding studies using the ultrafiltration method showed that the compound was subject to low protein binding (<40%) and was independent of the substrate concentration over a range of 1–16 µg/ml. Pharmacokinetic parameters of the compound were determined after intravenous and oral administration of 0.6, 2 and 8 mg/kg doses using a model independent method. After oral administration, the compound showed the double-peak phenomenon, which could be due to the high water solubility (log P, 1.01 ± 0.01), regional differences in the gastrointestinal absorption and enterohepatic recirculation effects. The absorption of CDRI-93/478 was rapid and showed a bioavailability of 69.9 ± 5.1% (mean ± S. D.) after 2 and 8 mg/kg oral dose. However, the pharmacokinetic parameters of the compound could not be determined after the 0.6 mg/kg oral dose due to insufficient data points. The studies following intravenous and oral administration demonstrated linear pharmacokinetics, low clearance and high volume of distribution over the dose range studied. The excretion studies after the 8 mg/kg oral dose indicated that the compound was not excreted through the feces and the urinary excretion was very low (<2%).

Key words

Antihypertensives - Arylpiperazine, derivatives - CDRI-93/478, in situ absorption, pharmacokinetics - portal-venous concentration difference, protein binding, urinary excretion
 

  • References

  • 1 Sinha N, Jain S, Saxena AK, Anand N, Saxena RM, Dubey MP et al. Methods for preparing 1-[4-arylpiperazine-1-yl]3-[2-oxopyrrolidin/piperidin-1-yl] propanes. US Patent. 6084097 2000;
    PubMedGoogle Scholar
  • 2 Habucky K. Methods To Assess Absorption In Drug Discovery. In Welling PG, Tse FLS. eds Pharmacokinetics: Regulatory Industrial Academic Perspectives. Marcel Dekker: New York: 1995. p 30-34
    Google Scholar
  • 3 Doluisio JT, Billups NF, Diltert LW, Sugita ET, Swintosky JV. Drug absorption. I. An in situ rat gut technique yielding realistic absorption rates. J Pharm Sci. 1969; 58: 1196-99
    CrossrefPubMedGoogle Scholar
  • 4 Diamond L, Doluisio JT, Crouthamel WG. Physilogical factors affecting intestinal drug absorption. Eur J Pharmacol. 1970; 11: 111-114
    PubMedGoogle Scholar
  • 5 Tabata K, Yamaoka K, Fukuyama T, Nakagava T. Local absorption kinetics into the portal system using the portal venous concentration difference after an oral dose of diclofenac in the awakening rat. Drug Metab Dispos. 1996; 24: 216-20
    PubMedGoogle Scholar
  • 6 Koike Y, Magnusson A, Steiner E, Rane A, Sjogvist F. Ultrafiltration compared with equilibrium dialysis in determination of unbound phenytoin in plasma. Ther Drug Monit. 1985; 7: 461-465
    CrossrefPubMedGoogle Scholar
  • 7 Lowry OH, Rosebrough NJ, Farrm AL, Randall RJ. Protein measurement with the Folin Phenol reagent. J Biol Chem. 1951; 193: 265-275
    PubMedGoogle Scholar
  • 8 Lal J, Gupta RC. LC determination of the anti-ischemic and anti-hypertensive agent CDRI-93/478 in rat serum. J Pharm Biomed Anal. 2001; 26: 579-584
    CrossrefPubMedGoogle Scholar
  • 9 Gibaldi M, Perrier D. Pharmacokinetics. In Swarbrick J. ed Drugs and Pharmaceutical Sciences. Marcel Dekker: New York: 1982. p 409-417
    Google Scholar
  • 10 Kwon Y, Inskeep PB. Theoretical considerations on two equations for estimating the extent of absorption after oral administration of drugs. Pharm Res. 1996; 13: 566-69
    CrossrefPubMedGoogle Scholar
  • 11 Shah VP, Midha KK, Findlay JWA, Hill HM, Hulse ID, McGilveray II. Bioanalytical method validation-A revisit with a decade of progress. Pharm Res. 2000; 17: 1551-1557
    CrossrefPubMedGoogle Scholar
  • 12 Clements JA, Heading RC, Nimmo WS, Prescott LF. Kinetics of acetaminophen absorption and gastric emptying in man. Clin Pharmacol Ther. 1978; 24: 420-431
    PubMedGoogle Scholar
  • 13 Lui CY, Oberle R, Fleisher D, Amidon GL. Application of a radiotelemetric system to evaluate the performance of enteric coated and plain aspirin tablets. J Pharm Sci. 1986; 75: 469-474
    CrossrefPubMedGoogle Scholar
  • 14 Takamatsua N, Welageb LS, Hayashic Y, Yamamotod R, Barnette JL, Shah VP et al. Variability in cimetidine absorption and plasma double peaks following oral administration in the fasted state in humans: correlation with antral gastric motility. Eur J Pharm Biopharm. 2002; 53: 37-47
    CrossrefPubMedGoogle Scholar
  • 15 Dressman JB, Berardi RR, Elta GH, Gray TM, Montgomery PA, Lau HS et al. Absorption of flurbiprofen in the fed and fasted states. Pharm Res. 1992; 9: 901-907
    CrossrefPubMedGoogle Scholar
  • 16 Hammarlund MM, Paalzow LK, Odlind B. Pharmacokinetics of furosemide in man after intravenous and oral administration. Application of moment analysis. Eur J Clin Pharmacol. 1984; 26: 197-207
    CrossrefPubMedGoogle Scholar
  • 17 Bergstrom RF, Kay DR, Harkcom TM, Wagner JG. Penicillamine kinetics in normal subjects. Clin Pharmacol Ther. 1981; 30: 404-413
    CrossrefPubMedGoogle Scholar
  • 18 Piyapulrungroj N, Zhou YS, Li C, Liu G, Zimmerman E, Fleisher D. Cimetidine absorption and elimination in rat small intestine. Drug Metab Dispos. 2000; 28: 65-72
    PubMedGoogle Scholar
  • 19 Pedersen PV, Miller R. Pharmacokinetics and bioavailability of cimetidine in humans. J Pharm Sci. 1980; 69: 394-398
    CrossrefPubMedGoogle Scholar
  • 20 Pedersen PV. Pharmacokinetic analysis by linear system approach. I: Cimetidine bioavailability and second peak phenomenon. J Pharm Sci. 1981; 70: 32-38
    CrossrefPubMedGoogle Scholar
  • 21 Ichikdawa T, Ishida S, Sakiya Y, Sawada Y, Hanana M. Biliary excretion and enterohepatic cycling of glycyrrhizin in rats. J Pharm Sci. 1986; 75: 672-675
    CrossrefPubMedGoogle Scholar
  • 22 Hasselstrom J, Sawe J. Morphine pharmacokinetics and metabolism in humans: enterohepatic cycling and relative contribution of metabolites to active opioid concentrations. Clin Pharmacokinet. 1986; 24: 344-354
    PubMedGoogle Scholar
  • 23 Eeckhoudt SL, Evrard PA, Verbeeck RK. Biliary excretion and enterohepatic cycling of r- and s-flurbiprofen in the rats. Drug Metab Dispos. 1997; 25: 428-430
    PubMedGoogle Scholar
  • 24 Oberle RL, Amidon GL. The influence of variable gastric emptying and intestinal transit rates on the plasma level curve of cimetidine: an explanation for the double peak phenomenon. J Pharmacol Biopharm. 1987; 15: 529-544
    PubMedGoogle Scholar
  • 25 Lipka E, Lee ID, Langguth P, Spahn-Langguth H, Mutschler E, Amidon GL. Celiprolol double-peak occurrence and gastric motility: nonlinear mixed effects modeling of bioavailability data obtained in dogs. J Pharmacokinet Biopharm. 1995; 23: 267-286
    CrossrefPubMedGoogle Scholar
  • 26 Gugler R, Somogyi A, Bergmann KV. The biliary excretion of histamine H2-receptor antagonists cimetidine and oxmetidine. Clin Pharmacol Ther. 1981; 29: 249-250
    PubMedGoogle Scholar
  • 27 Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res. 1993; 10: 1093-1095
    CrossrefPubMedGoogle Scholar
  • 28 Rowland M, Tozer TN. Clinical Pharmacokinetics – Concepts and Applications. 3rd ed New Delhi: BI Waverly Pvt. Ltd.; 1995
    Google Scholar